Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib

Ann Oncol. 2015 Jul;26(7):1515-7. doi: 10.1093/annonc/mdv211. Epub 2015 Apr 28.

Authors

C F Spraggs¹, L R Parham², K Song³, L P Briley², T Johnson⁴, M Russo³, H Tada³, A du Bois⁵, C-F Xu⁴

Affiliations

¹ GlaxoSmithKline Research and Development, Stevenage, UK [email protected].
² PAREXEL International, Durham, Philadelphia, USA.
³ GlaxoSmithKline Research and Development, Philadelphia, USA.
⁴ GlaxoSmithKline Research and Development, Stevenage, UK.
⁵ Kliniken Essen-Mitte, Essen, Germany.

PMID: 25922065
DOI: 10.1093/annonc/mdv211

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Apoptosis Regulatory Proteins / genetics*
Bcl-2-Like Protein 11
Gene Deletion*
Humans
Indazoles
Indoles / therapeutic use*
Lapatinib
Membrane Proteins / genetics*
Neoplasms / drug therapy
Neoplasms / genetics*
Neoplasms / pathology
Polymorphism, Genetic / genetics*
Prognosis
Prospective Studies
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins / genetics*
Pyrimidines / therapeutic use*
Pyrroles / therapeutic use*
Quinazolines / therapeutic use*
Signal Transduction / drug effects
Sulfonamides / therapeutic use*
Sunitinib

Substances

Angiogenesis Inhibitors
Apoptosis Regulatory Proteins
BCL2L11 protein, human
Bcl-2-Like Protein 11
Indazoles
Indoles
Membrane Proteins
Protein Kinase Inhibitors
Proto-Oncogene Proteins
Pyrimidines
Pyrroles
Quinazolines
Sulfonamides
Lapatinib
pazopanib
Sunitinib